{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T01:17:42Z","timestamp":1728177462731},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,10]]},"DOI":"10.7759\/cureus.55925","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T06:58:00Z","timestamp":1710140280000},"source":"Crossref","is-referenced-by-count":1,"title":["Naldemedine and Magnesium Oxide as First-Line Medications for Opioid-Induced Constipation: A Comparative Database Study in Japanese Patients With Cancer Pain"],"prefix":"10.7759","author":[{"given":"Takaomi","family":"Kessoku","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Higashibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhide","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Naya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Koretaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Hisanaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnw255","article-title":"Opioid-induced constipation and bowel dysfunction: a clinical guideline","volume":"18","author":"M\u00fcller-Lissner S","year":"2017","unstructured":"M\u00fcller-Lissner S, Bassotti G, Coffin B, et al.. Opioid-induced constipation and bowel dysfunction: a clinical guideline. Pain Med. 2017, 18:1837-63. 10.1093\/pm\/pnw255","journal-title":"Pain Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/141737","article-title":"Opioid-induced constipation: pathophysiology, clinical consequences, and management","volume":"2014","author":"Kumar L","year":"2014","unstructured":"Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract. 2014, 2014:141737. 10.1155\/2014\/141737","journal-title":"Gastroenterol Res Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.016","article-title":"American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation","volume":"156","author":"Crockett SD","year":"2019","unstructured":"Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S. American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation. Gastroenterology. 2019, 156:218-26. 10.1053\/j.gastro.2018.07.016","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2009.0014","article-title":"Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey","volume":"5","author":"Bell T","year":"2009","unstructured":"Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag. 2009, 5:137-44. 10.5055\/jom.2009.0014","journal-title":"J Opioid Manag"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5704627","article-title":"Incidence and health related quality of life of opioid-induced constipation in chronic noncancer pain patients: a prospective multicentre cohort study","volume":"2018","author":"Veiga DR","year":"2018","unstructured":"Veiga DR, Mendon\u00e7a L, Sampaio R, Lopes JC, Azevedo LF. Incidence and health related quality of life of opioid-induced constipation in chronic noncancer pain patients: a prospective multicentre cohort study. Pain Res Treat. 2018, 2018:5704627. 10.1155\/2018\/5704627","journal-title":"Pain Res Treat"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2008.00495.x","article-title":"The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1)","volume":"10","author":"Bell TJ","year":"2009","unstructured":"Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009, 10:35-42. 10.1111\/j.1526-4637.2008.00495.x","journal-title":"Pain Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjpain.2015.12.007","article-title":"Opioid-induced constipation, use of laxatives, and health-related quality of life","volume":"11","author":"Christensen HN","year":"2016","unstructured":"Christensen HN, Olsson U, From J, Breivik H. Opioid-induced constipation, use of laxatives, and health-related quality of life. Scand J Pain. 2016, 11:104-10. 10.1016\/j.sjpain.2015.12.007","journal-title":"Scand J Pain"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2021.0438","article-title":"Revision of pharmacological treatment recommendations for cancer pain: clinical guidelines from the Japanese Society of Palliative Medicine","volume":"25","author":"Mawatari H","year":"2022","unstructured":"Mawatari H, Shinjo T, Morita T, Kohara H, Yomiya K. Revision of pharmacological treatment recommendations for cancer pain: clinical guidelines from the Japanese Society of Palliative Medicine. J Palliat Med. 2022, 25:1095-114. 10.1089\/jpm.2021.0438","journal-title":"J Palliat Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9610(01)00782-6","article-title":"Incidence, prevalence, and management of opioid bowel dysfunction","volume":"182","author":"Pappagallo M","year":"2001","unstructured":"Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001, 182:11S-8S. 10.1016\/s0002-9610(01)00782-6","journal-title":"Am J Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e318237d626","article-title":"A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction","volume":"28","author":"Ishihara M","year":"2012","unstructured":"Ishihara M, Ikesue H, Matsunaga H, et al.. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain. 2012, 28:373-81. 10.1097\/AJP.0b013e318237d626","journal-title":"Clin J Pain"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/nu13020421","article-title":"Magnesium oxide in constipation","volume":"13","author":"Mori H","year":"2021","unstructured":"Mori H, Tack J, Suzuki H. Magnesium oxide in constipation. Nutrients. 2021, 13:421. 10.3390\/nu13020421","journal-title":"Nutrients"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.0853","article-title":"Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer","volume":"35","author":"Katakami N","year":"2017","unstructured":"Katakami N, Harada T, Murata T, et al.. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol. 2017, 35:3859-66. 10.1200\/JCO.2017.73.0853","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-06807-y","article-title":"Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan","volume":"30","author":"Takata K","year":"2022","unstructured":"Takata K, Nakazawa M, Honda K, Hashimoto S. Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan. Support Care Cancer. 2022, 30:3943-54. 10.1007\/s00520-022-06807-y","journal-title":"Support Care Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57111233","article-title":"Real-world patient characteristics and treatment patterns of naldemedine for the treatment of opioid-induced constipation in patients with cancer: a multicenter retrospective chart review study","volume":"57","author":"Hiruta E","year":"2021","unstructured":"Hiruta E, Fujita Y, Imai H, et al.. Real-world patient characteristics and treatment patterns of naldemedine for the treatment of opioid-induced constipation in patients with cancer: a multicenter retrospective chart review study. Medicina (Kaunas). 2021, 57:1233. 10.3390\/medicina57111233","journal-title":"Medicina (Kaunas)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04884-0","article-title":"A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting","volume":"28","author":"Sato J","year":"2020","unstructured":"Sato J, Tanaka R, Ishikawa H, Suzuki T, Shino M. A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting. Support Care Cancer. 2020, 28:1083-8. 10.1007\/s00520-019-04884-0","journal-title":"Support Care Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118048","article-title":"Preventive effects of naldemedine, peripherally acting \u03bc-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets","volume":"257","author":"Kanemasa T","year":"2020","unstructured":"Kanemasa T, Matsuzaki T, Koike K, Hasegawa M, Suzuki T. Preventive effects of naldemedine, peripherally acting \u03bc-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets. Life Sci. 2020, 257:118048. 10.1016\/j.lfs.2020.118048","journal-title":"Life Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5056\/jnm18194","article-title":"A randomized double-blind placebo-controlled trial on the effect of magnesium oxide in patients with chronic constipation","volume":"25","author":"Mori S","year":"2019","unstructured":"Mori S, Tomita T, Fujimura K, et al.. A randomized double-blind placebo-controlled trial on the effect of magnesium oxide in patients with chronic constipation. J Neurogastroenterol Motil. 2019, 25:563-75. 10.5056\/jnm18194","journal-title":"J Neurogastroenterol Motil"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12600","article-title":"Antacid attenuates the laxative action of magnesia in cancer patients receiving opioid analgesic","volume":"68","author":"Ibuka H","year":"2016","unstructured":"Ibuka H, Ishihara M, Suzuki A, Kagaya H, Shimizu M, Kinosada Y, Itoh Y. Antacid attenuates the laxative action of magnesia in cancer patients receiving opioid analgesic. J Pharm Pharmacol. 2016, 68:1214-21. 10.1111\/jphp.12600","journal-title":"J Pharm Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092112","article-title":"Effectiveness of naldemedine compared with magnesium oxide in preventing opioid-induced constipation: a randomized controlled trial","volume":"14","author":"Ozaki A","year":"2022","unstructured":"Ozaki A, Kessoku T, Tanaka K, et al.. Effectiveness of naldemedine compared with magnesium oxide in preventing opioid-induced constipation: a randomized controlled trial. Cancers (Basel). 2022, 14:2112. 10.3390\/cancers14092112","journal-title":"Cancers (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-023-00520-2","article-title":"A nationwide hospital claims database analysis of real-world patterns of laxative use for opioid-induced constipation in Japanese patients with cancer","volume":"12","author":"Higashibata T","year":"2023","unstructured":"Higashibata T, Kessoku T, Morioka Y, et al.. A nationwide hospital claims database analysis of real-world patterns of laxative use for opioid-induced constipation in Japanese patients with cancer. Pain Ther. 2023, 12:993-1003. 10.1007\/s40122-023-00520-2","journal-title":"Pain Ther"},{"key":"ref21","unstructured":"MDV database overview. (2023). Accessed. January 24, 2023: https:\/\/en.mdv.co.jp\/about-mdv-database\/mdv-database-overview\/."},{"key":"ref22","unstructured":"Ethical guidelines for medical and health research involving human subjects. (2022). Accessed. May 12, 2023: https:\/\/www.mhlw.go.jp\/content\/000769921.pdf."},{"key":"ref23","unstructured":"SYMPROIC\u00ae (naldemedine) tablets, for oral use, C-II. (2017). Accessed. January 22, 2023: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208854s000lbl.pdf."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07002-9","article-title":"Risk factors for opioid-induced constipation in cancer patients: a single-institution, retrospective analysis","volume":"30","author":"Kanbayashi Y","year":"2022","unstructured":"Kanbayashi Y, Ishizuka Y, Shimizu M, Sawa S, Yabe K, Uchida M. Risk factors for opioid-induced constipation in cancer patients: a single-institution, retrospective analysis. Support Care Cancer. 2022, 30:5831-6. 10.1007\/s00520-022-07002-9","journal-title":"Support Care Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278823","article-title":"Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: a subgroup analysis","volume":"17","author":"Kanbayashi Y","year":"2022","unstructured":"Kanbayashi Y, Shimizu M, Ishizuka Y, Sawa S, Yabe K, Uchida M. Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: a subgroup analysis. PLoS One. 2022, 17:e0278823. 10.1371\/journal.pone.0278823","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S61602","article-title":"Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review","volume":"6","author":"Coyne KS","year":"2014","unstructured":"Coyne KS, LoCasale RJ, Datto CJ, Sexton CC, Yeomans K, Tack J. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes Res. 2014, 6:269-81. 10.2147\/CEOR.S61602","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2224-5820.2012.07.08","article-title":"Opioid-induced nausea and vomiting","volume":"1","author":"Smith HS","year":"2012","unstructured":"Smith HS, Smith JM, Seidner P. Opioid-induced nausea and vomiting. Ann Palliat Med. 2012, 1:121-9. 10.3978\/j.issn.2224-5820.2012.07.08","journal-title":"Ann Palliat Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2658","article-title":"Use of naldemedine is associated with reduced incidence of hyperactive delirium in cancer patients with opioid-induced constipation: a nationwide retrospective cohort study in Japan","volume":"42","author":"Abe H","year":"2022","unstructured":"Abe H, Sumitani M, Matsui H, Inoue R, Fushimi K, Uchida K, Yasunaga H. Use of naldemedine is associated with reduced incidence of hyperactive delirium in cancer patients with opioid-induced constipation: a nationwide retrospective cohort study in Japan. Pharmacotherapy. 2022, 42:241-9. 10.1002\/phar.2658","journal-title":"Pharmacotherapy"},{"key":"ref29","article-title":"New edition of cancer palliative care guidebook","author":"Ogawa A","year":"2019","unstructured":"Ogawa A, Kizawa Y, Yamamoto R. New edition of cancer palliative care guidebook. Seikaisha, Tokyo, Japan; 2019."},{"key":"ref30","article-title":"Pain clinic treatment policy revision","year":"2019","unstructured":"Pain clinic treatment policy revision. Shinko Trading Company Ltd., Tokyo, Japan; 2019."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199141030-00002","article-title":"Opioid agonist-antagonist drugs in acute and chronic pain states","volume":"41","author":"Hoskin PJ","year":"1991","unstructured":"Hoskin PJ, Hanks GW. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs. 1991, 41:326-44. 10.2165\/00003495-199141030-00002","journal-title":"Drugs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/223338-naldemedine-and-magnesium-oxide-as-first-line-medications-for-opioid-induced-constipation-a-comparative-database-study-in-japanese-patients-with-cancer-pain","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T06:58:09Z","timestamp":1710140289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/223338-naldemedine-and-magnesium-oxide-as-first-line-medications-for-opioid-induced-constipation-a-comparative-database-study-in-japanese-patients-with-cancer-pain"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,10]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.55925","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,10]]}}}